secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0000784199-22-000122
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q1 revenue up 8.6% to $77.2M; net loss of $0.08 per share
------------------------------------------------------------------

- Revenue $77.2M, +8.6% GAAP YoY; constant currency growth 11.2% driven by aortic stent grafts (+34%) and On-X (+11%).
- Net loss $3.4M ($0.08/share) vs $3.1M loss in Q1 2021; non-GAAP net income $1.1M ($0.03/share) vs $1.4M.
- Asia Pacific constant currency revenue +39%; Latin America +93%. Pipeline progress: PROACT Mitral and PerClot FDA PMA expected in 2022.
- FY 2022 constant currency revenue growth guidance reaffirmed at 9.0%-11.0%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419922000122/0000784199-22-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419922000122/aort-20220505x8k.htm
  HTML page:      https://secwatch.observer/filing/0000784199-22-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer